Campaigners hope this will be a milestone in unlocking finances for expensive anti-venoms, providing impetus for research and enabling more coordinated interventions.
Poisonous snake bites kill about 90,000 people a year, thousands more than other deadly NTDs, and leave a further 400,000 with lost limbs, blindness and trauma. They particularly affect the very poor, such as barefoot farmers in low- and middle-income countries.
Tackling the problem is tricky for various reasons: for example, victims are often in remote areas and need treatment fast; health workers cannot easily identify the culprit with certainty; and anti-venom treatments are expensive.
The WHO resolution is sponsored by Costa Rica and Colombia and co-sponsored by 25 other countries. It urges countries to assess impacts, share antivenom technology, support research on new medical tools, and educate health workers about how to respond.
“It’s a visionary proposal but are we prepared to do all this in the field? [In India] we have a snakebite protocol that was published ten years back but how many hospitals follow this protocol?”
“We are really glad to see that quite a large number of countries are supporting it,” says Julien Potet of the medical charity Doctors without Borders (Medécins Sans Frontières-MSF). “But it’s a first step … the next step is to really translate this resolution into a concrete plan at country level as well as an ambitious roadmap.”
Rafael Ruiz de Castañeda, of the Institute of Global Health in Geneva, agrees: “We feel that things are moving in a good direction but it’s only the beginning.”
As part of the resolution’s call to accelerate global efforts, in August the WHO will publish an eagerly awaited roadmap prioritising five action areas to encourage funding from donors.
Jose Louies, a wildlife expert from the Indian Snakebite Initiative, questions who will implement the roadmap on the ground. “It’s a visionary proposal but are we prepared to do all this in the field? [In India] we have a snakebite protocol that was published ten years back but how many hospitals follow this protocol?”
One key issue, which MSF has been campaigning on, is the need to manufacture more anti-venoms. Production is expensive and the products — biological agents generated by manipulating the immune system of horses — have a short shelf-life.
The drug company Sanofi produced the last batch of its effective anti-venom in 2014. This means people affected by snake bites turn to poor-quality, cheaper anti-venoms.
MSF wants countries to band together to leverage better purchasing power with manufacturers, says its NTD adviser Julien Potet, drawing parallels with GAVI, a public-private alliance that has improved access to vaccines with this approach.
Another key issue is the dearth of basic information about the incidence of snakebite. “This is not only a humanitarian crisis… it’s a data crisis,” Castañeda tells SciDev.Net.
A few countries are trying to gather data. In India, where an estimated 50,000 people die of snakebite each year, the Big 4 Mapping Project has just completed its first year of real-time mapping to help build a picture of snake activity across the country. It involved enlisting around a thousand screened volunteers — including snake-rescuers, naturalists and forestry workers — to upload photograph sightings of India’s four most medically important snakes, along with information such as location, time of day and weather. Louies, who runs the project, hopes to add mapping of actual snake bites and anti-venom stockists over the next few years.
Another project that began in March in Nepal and Cameroon, Snake-Byte, is looking to understand the epidemiology and impact of snakebite.
And an app developed by the same team at the Institute of Global Health, dubbed SNAPP, will use machine learning to help health workers by identifying a snake from a photo supplied by them, a victim or a bystander. MSF has recently signed up to collaborate with SNAPP, to contribute images and later test clinical applications of the tool.